Sign in
CompletedPhase 3

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Key facts

Who runs it
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
228 people enrolled
Started
19 Sept 2024
Ended
13 Aug 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GR1802
  • Placebo
Record updated
29 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Diagnosed as CRSwNP and treated with systemic glucocorticoid within 2 years before screening; and/or those who had undergone surgery for nasal polyps before screening
  • An endoscopic bilateral NPS at screening/lead-in period and the baseline period of at least 5 out of a maximum score of 8 (with a minimum socre of 2 in each nasal cavity)
  • Nasal congestion/blockade/obstruction with moderate or severe symptom severity at at screening period (score 2 or 3 )
  • Willing to sign an informed consent, able to comply with clinic visits and study-related procedures as per protocol

Who cannot take part

  • Biologic therapy within 5 half-lives or within 10 weeks before baseline
  • Anti-IL-4Rα antibody before screening
  • An experimental drug within 5 half-lives or 1 months before baseline
  • Initiation of allergen immunotherapy within 3 months before screening
  • Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days
  • Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening
  • Systemic immunosuppressant to treat inflammatory disease or autoimmune disease within 2 months or 5 half-lives before baseline
  • Acute sinusitis or upper respiratory infection within a defined time period before screening
  • A nasal cavity tumor (malignant or benign)
  • Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis)
  • Participants with FEV1 50% or less of predicted normal were excluded
  • Evidence of fungal rhinosinusitis
  • Rhinitis medicamentosa
  • Nasal septal deviation occluding at least one nostril
  • Antrochoanal polyps
  • Pregnant or lactating woman

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are:

Read full original descriptionShow less

1. Does GR1802 reduce the need for surgery and systemic corticosteroid use? 2. What medical problems do participants have when taking GR1802?

Researchers will compare GR1802 to a placebo (a look-alike substance that contains no drug) to see if GR1802 works to treat CRSwNP.

Participants will:

Take GR1802 or a placebo once every 2 weeks for 13months. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms and the dosage and number of times they use mometasone furoate nasal spray.

The 2 groups in the trial

  • GR1802 groupTreatment being tested

    GR1802 300mg is administrated every 2 weeks (first dose doubled) for a total of 26 doses, of which an additional 2 ml of placebo is given at week 24.

    Treatment: GR1802

  • placebo groupPlacebo, for comparison

    Placebo is administered every 2 weeks for the first 16 weeks. GR1802 is given every 2 weeks from week 24 to W50.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps
Record updated
29 October 2026